Status: Recruiting
Rezafungin for Treatment of Pneumocystis Pneumonia in HIV Adults
This study aims to generate clinical data on the efficacy, safety, and tolerability of rezafungin combined with 7 days of co-trimoxazole for treatment of Pneumocystis pneumonia (PCP) in adults living with human immunodeficiency virus (HIV), which would expand the knowledge of clinical use of rezafungin.
Participants needed: 50
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Mundipharma Research LimitedUpdated: Apr 3, 2025Locations: 6
Eligibility criteria
Males or females at least 18 years of age. [+7]
Under 18 years of age. [+20]